Merck pays $35M to Kelun-Biotech for rights to investigational antibody drug conjugate

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Merck announced positive topline results from the pivotal phase III MK-3475A-D77 trial.

November 22, 2024

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Clinical and real-world data for the 9-valent human papillomavirus vaccine, Gardasil 9, evaluating the burden and incidence of certain HPV-related cancers and diseases, were presented at the International Papillomavirus Conference 2024 in Edinburgh, UK, from Nov. 12-15.

November 15, 2024

Vol.50 No.43

In Brief

Merck acquires Modifi Biosciences

Modifi Biosciences Inc., a Yale University spinout company formed in 2021 that develops direct DNA-modification-enabled cancer therapeutics, has been acquired by Merck.

October 25, 2024

Vol.50 No.40

Regulatory News

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Adjuvant Keytruda prolongs DFS in high-risk bladder cancer

Results from a large phase III clinical trial show that treatment with Keytruda (pembrolizumab) may nearly double the length of time people with high-risk muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Follow-up data from the phase IIb randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with Keytruda in patients with resected high-risk melanoma (stage 3/4) following complete resection.

September 20, 2024

Vol.50 No.35

Merck pays $35M to Kelun-Biotech for rights to investigational antibody drug conjugate

YOU MAY BE INTERESTED IN

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Merck acquires Modifi Biosciences

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

Adjuvant Keytruda prolongs DFS in high-risk bladder cancer

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Renew today!

Subscriber content

Never miss an issue!

Login

Merck pays $35M to Kelun-Biotech for rights to investigational antibody drug conjugate

YOU MAY BE INTERESTED IN

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Merck acquires Modifi Biosciences

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck

Adjuvant Keytruda prolongs DFS in high-risk bladder cancer

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Never miss an issue!

Login

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck